Shares of Silo Pharma, Inc. (SILO) are surging more than 50% Friday morning after the company reported positive data for its drug candidate SPU-21 for the treatment of Arthritis.
The company today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents.
Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).
SILO, currently at $5.21, has traded in the range of $0.17-$12.45 in the last 1 year.
Source: Read Full Article
Lates News:
-
US Presidential Candidate Pledges Dollar Backing With Bitcoin, No Bitcoin Capital Gains Tax
-
MicroStrategy's Michael Saylor Signals Elon Musk to Purchase More Bitcoin
-
Elon Musk Fires Back At Twitter with a Counter Lawsuit
-
Jordan Peterson Sparks Discussion on Bitcoin vs. Traditional Banks
-
Key Metric Suggests Institutional Traders Have Completed Their BTC Accumulation — Bullish Move Incoming?